Despite the conventional need for patients to travel to MRI devices, the use of a point-of-care, portable scanner has proven to be a feasible method of acquiring clinically useful images.
New data suggest a switch from natalizumab to a high efficacy disease-modifying therapy for patients with multiple sclerosis is more beneficial than switching to moderate efficacy therapy, including a lower risk of disease activity.
.png)
.png)
